Latest News
Acousia Therapeutics completes patient enrolment in Phase 2 trial of Bimokalner
9 January 2026 - Acousia Therapeutics GmbH, a clinical-stage biotechnology company based in Germany, announced on Thursday that it has completed patient enrolment in its Phase 2 PROHEAR clinical study of ACOU085 (INN: Bimokalner).Bimokalner is a prop...
ZYUS Life Sciences reports positive preliminary results from Phase 2a trial of Trichomylin softgel
9 January 2026 - Clinical-stage life sciences company ZYUS Life Sciences Corporation (TSXV:ZYUS) on Thursday reported favourable preliminary results from its ongoing Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evalu...
DELFI Diagnostics names new chief financial officer
9 January 2026 - DELFI Diagnostics Inc, a developer of next-generation, blood-based tests to help detect cancer, announced on Thursday the appointment of Cindy Soriano as chief financial officer, effective immediately.Soriano brings 20 years of finan...
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
8 January 2026 - Saluda Medical, Inc. (ASX: SLD), an American commercial-stage medical device company, said on Thursday that its next-generation EVA Sensing Technology has received CE certification for commercialisation in Europe, with recognition of...
Organon signs commercialisation agreement for Nilemdo across six European markets
8 January 2026 - US healthcare company Organon (NYSE:OGN) announced on Thursday that it has entered into a commercialisation agreement with Daiichi Sankyo Europe to distribute and promote Nilemdo in France, Denmark, Iceland, Sweden, Finland, and Norw...